Related references
Note: Only part of the references are listed.A Phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock
Naoki Aikawa et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2013)
A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock
Peter E. Morris et al.
CRITICAL CARE (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008
R. Phillip Dellinger et al.
CRITICAL CARE MEDICINE (2008)
Safety and efficacy of affinity-purified, anti-tumor necrosis factor-α, ovine fab for injection (CytoFab) in severe sepsis
Todd W. Rice et al.
CRITICAL CARE MEDICINE (2006)
Neutralization of tumor necrosis factor in preclinical models of sepsis
JA Lorente et al.
SHOCK (2005)
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab1)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels
EA Panacek et al.
CRITICAL CARE MEDICINE (2004)
Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed
KA Robinson et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2002)
Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study
E Abraham et al.
CRITICAL CARE MEDICINE (2001)
Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
DC Angus et al.
CRITICAL CARE MEDICINE (2001)
A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome
J Gallagher et al.
INTENSIVE CARE MEDICINE (2001)
Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice
B Echtenacher et al.
INFECTION AND IMMUNITY (2001)
Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study
K Reinhart et al.
CRITICAL CARE MEDICINE (2001)
The potential for HIV fusion inhibition
N Cammack
CURRENT OPINION IN INFECTIOUS DISEASES (2001)
Anti-inflammatory therapies in sepsis and septic shock
BD Freeman et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2000)
Share Paper
